Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Aurora Bay Area Medical Group-Marinette
mi
from
Marinette, WI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Aurora Bay Area Medical Group-Marinette
mi
from
Marinette, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
SIH Cancer Institute
mi
from
Carterville, IL
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
SIH Cancer Institute
mi
from
Carterville, IL
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Northeast Georgia Medical Center-Gainesville
mi
from
Gainesville, GA
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Northeast Georgia Medical Center-Gainesville
mi
from
Gainesville, GA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Brighton
mi
from
Brighton, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Brighton
mi
from
Brighton, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
First Dayton Cancer Care
mi
from
Kettering, OH
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
First Dayton Cancer Care
mi
from
Kettering, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Toledo Children's Hospital
mi
from
Toledo, OH
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Toledo Children's Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Columbia Saint Mary's Hospital - Ozaukee
mi
from
Mequon, WI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Columbia Saint Mary's Hospital - Ozaukee
mi
from
Mequon, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Columbia Saint Mary's Water Tower Medical Commons
mi
from
Milwaukee, WI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Columbia Saint Mary's Water Tower Medical Commons
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Medical Center of Central Georgia
mi
from
Macon, GA
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Medical Center of Central Georgia
mi
from
Macon, GA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Brighton
mi
from
Brighton, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Brighton
mi
from
Brighton, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Chelsea
mi
from
Chelsea, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Chelsea
mi
from
Chelsea, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Michigan Breast Specialists-Grosse Pointe Woods
mi
from
Grosse Pointe Woods, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Michigan Breast Specialists-Grosse Pointe Woods
mi
from
Grosse Pointe Woods, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Associates of Saginaw Valley PC
mi
from
Saginaw, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Associates of Saginaw Valley PC
mi
from
Saginaw, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Cancer Care Center-Caldwell
mi
from
Caldwell, ID
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Caldwell
mi
from
Caldwell, ID
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Walter Knox Memorial Hospital
mi
from
Emmett, ID
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Walter Knox Memorial Hospital
mi
from
Emmett, ID
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Nampa
mi
from
Nampa, ID
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Nampa
mi
from
Nampa, ID
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Canton
mi
from
Canton, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Canton
mi
from
Canton, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Caro Cancer Center
mi
from
Caro, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Caro Cancer Center
mi
from
Caro, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Chelsea
mi
from
Chelsea, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Chelsea
mi
from
Chelsea, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Consultants-Clarkston
mi
from
Clarkston, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Consultants-Clarkston
mi
from
Clarkston, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Newland Medical Associates-Clarkston
mi
from
Clarkston, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Newland Medical Associates-Clarkston
mi
from
Clarkston, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Genesee Cancer & Blood Disease Treatment Center, PC
mi
from
Flint, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Genesee Cancer & Blood Disease Treatment Center, PC
mi
from
Flint, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Genesee Hematology Oncology PC
mi
from
Flint, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Genesee Hematology Oncology PC
mi
from
Flint, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
mi
from
Grosse Pointe Woods, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
mi
from
Grosse Pointe Woods, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Hope Cancer Clinic
mi
from
Livonia, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Hope Cancer Clinic
mi
from
Livonia, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology-Pontiac
mi
from
Pontiac, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology-Pontiac
mi
from
Pontiac, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Hope Cancer Center
mi
from
Pontiac, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Hope Cancer Center
mi
from
Pontiac, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Newland Medical Associates-Pontiac
mi
from
Pontiac, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Newland Medical Associates-Pontiac
mi
from
Pontiac, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Great Lakes Cancer Management Specialists-Rochester Hills
mi
from
Rochester Hills, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Great Lakes Cancer Management Specialists-Rochester Hills
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Bhadresh Nayak MD PC-Sterling Heights
mi
from
Sterling Heights, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Bhadresh Nayak MD PC-Sterling Heights
mi
from
Sterling Heights, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Great Lakes Cancer Management Specialists-Macomb Professional Building
mi
from
Warren, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Great Lakes Cancer Management Specialists-Macomb Professional Building
mi
from
Warren, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Macomb Hematology Oncology PC
mi
from
Warren, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Macomb Hematology Oncology PC
mi
from
Warren, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Michigan Breast Specialists-Warren
mi
from
Warren, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Michigan Breast Specialists-Warren
mi
from
Warren, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Huron Gastroenterology PC
mi
from
Ypsilanti, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Huron Gastroenterology PC
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Ann Arbor
mi
from
Ypsilanti, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Ann Arbor
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Baker City
mi
from
Baker City, OR
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Baker City
mi
from
Baker City, OR
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Medical Center-Ontario
mi
from
Ontario, OR
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Medical Center-Ontario
mi
from
Ontario, OR
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic Stevens Point Center
mi
from
Stevens Point, WI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic Stevens Point Center
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Franciscan Health Indianapolis
mi
from
Indianapolis, IN
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Franciscan Health Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas-Manhattan
mi
from
Manhattan, KA
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas-Manhattan
mi
from
Manhattan, KA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - McPherson
mi
from
McPherson, KA
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - McPherson
mi
from
McPherson, KA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Bon Secours Memorial Regional Medical Center
mi
from
Mechanicsville, VA
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Bon Secours Memorial Regional Medical Center
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Michigan Breast Specialists-Macomb Township
mi
from
Macomb, MI
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Michigan Breast Specialists-Macomb Township
mi
from
Macomb, MI
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Harold Alfond Center for Cancer Care
mi
from
Augusta, ME
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Harold Alfond Center for Cancer Care
mi
from
Augusta, ME
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Eastern Maine Medical Center
mi
from
Bangor, ME
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Eastern Maine Medical Center
mi
from
Bangor, ME
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated:  12/31/1969
Lafayette Family Cancer Center-EMMC
mi
from
Brewer, ME
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Enrolling
Updated: 12/31/1969
Lafayette Family Cancer Center-EMMC
mi
from
Brewer, ME
Click here to add this to my saved trials